← Every company
ACADIA Pharmaceuticals Inc Patents
What ACADIA Pharmaceuticals Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
ACAD on carbonthat →Filings on file
11
Granted
0
Still pending
11
Filed under
3 names
11 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| CRYSTALLINE FORMS OF TROFINETIDEA61P 25/00, C07D 207/16, C07K 5/0806, A61K 9/0095, A61K 31/40, A61K 38/00, C07B2200/13, C07K 14/475Filed as ACADIA Pharmaceuticals Inc.2025-11-10Matthew PETERSON | pending |
| NEURO-ATTENUATING KETAMINE AND NORKETAMINE COMPOUNDS, DERIVATIVES THEREOF, AND METHODSA61K 31/133, C07B 59/001, C07C 225/20, C07C2601/14, A61P 25/28, A61P 25/02, A61P 25/22, A61P 25/24, A61K 9/2009, A61K 9/2013, A61K 9/2018, A61K 9/2027, A61K 9/2031, A61K 9/2054, A61K 9/2059, A61K 31/135, A61K 31/215, A61K 45/06, C07B 59/00, C07B2200/05, A61K2300/00Filed as ACADIA Pharmaceuticals Inc.2025-10-13Alex Nivorozhkin | pending |
| MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88Filed as ACADIA PHARMACEUTICALS INC.2025-09-05MARTIN QUIBELL | pending |
| MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88A61K 31/165, C07C 233/22, C07D 213/56, C07C2601/08, C07C2602/18, C07C2602/42, C07C2602/44, C07C2601/14, A61P 25/14, A61P 25/28, A61P 25/18, A61P 25/24, A61P 25/00, A61P 25/16, A61K 31/277, A61K 31/415, A61K 31/4402, C07B 59/001, C07B2200/05, C07B2200/07, C07C 235/34, C07C 237/20, C07C 255/41, C07C 255/46, C07C 323/17, C07D 231/12Filed as ACADIA Pharmaceuticals Inc.2024-12-12Martin Quibell | pending |
| MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88A61K 31/337, C07D 305/08, A61P 25/00, A61K 31/165, A61K 31/381, A61K 31/4402, A61K 31/4412, A61K 31/4427, C07B 59/001, C07B2200/05, C07B2200/07, C07C 233/16, C07C 235/34, C07C 237/20, C07C 255/41, C07D 213/56, C07D 213/65, C07D 233/16, C07D 333/24, C07D 405/12Filed as ACADIA Pharmaceuticals Inc.2024-12-12Martin Quibell | pending |
| M4 POSITIVE ALLOSTERIC MODULATORSFiled as ACADIA PHARMACEUTICALS INC.2024-12-06OSAMU KURASAWA | pending |
| M4 POSITIVE ALLOSTERIC MODULATORSFiled as ACADIA PHARMACEUTICALS INC.2024-12-06OSAMU KURASAWA | pending |
| COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASESC07D 211/58, C07D 413/12, A61P 25/00, A61K 31/4468, A61K 31/4525, C07D 401/12, C07D 403/12, C07D 405/12, C07D 409/12, C07D 417/12, C07D 451/04, C07D 471/04Filed as ACADIA Pharmaceuticals Inc.2024-09-27Ethan S. Burstein | pending |
| MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88Filed as ACADIA Pharmaceuticals Inc.2024-09-05Martin Quibell | pending |
| COMPOSITIONS FOR TREATMENT OF DISEASES AND CONDITIONSFiled as ACADIA PHARMACEUTICALS INC.2024-08-01ETHAN S. BURSTEIN | pending |
| COMPOSITIONS FOR TREATMENT OF DISEASES AND CONDITIONSFiled as Acadia Pharmaceuticals, Inc.2024-02-16Ethan S. BURSTEIN | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on ACAD
Company overviewEverything on ACAD in one place, with the price.SEC filingsWhat ACAD's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat ACAD's own officers and directors buy and sell.Who owns itEvery manager reporting a position in ACAD.Funds holding itWhich funds and ETFs hold ACAD, and how big a bet.LobbyingWhat ACAD spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on ACAD's account, and who they worked for.